Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917644 · ClinicalTrials.gov registry record · Phase 4
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT00917644 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 76 participants.
The verdict
NCT00917644, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
Interventions
- DRUG Atorvastatin
- GENETIC Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00917644
The ClinicalTrials.gov registry entry for NCT00917644 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atorvastatin is the first listed.
NCT00917644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00917644 about?
NCT00917644 is a clinical study titled "Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet". To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
What is the current status of trial NCT00917644?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2008-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00917644?
The interventions under investigation include: Atorvastatin (DRUG), Atorvastatin (GENETIC).
Who is sponsoring clinical trial NCT00917644?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.